Home  /  Resource Library  /  Bendamustine plus Rituximab Versus R-CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

Bendamustine plus Rituximab Versus R-CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

Results of a study comparing Bendamustine plus Rituximab with R-CHOP as first line treatment for grade 3A follicular lymphoma.